Apnimed, Inc. (NASDAQ: APMD) is a Healthcare company (Biotechnology) with a market capitalization of $741M. The Maz Rating grades it against the other companies in its sector.
Apnimed, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.80, Apnimed, Inc. trades at 3.8x trailing earnings, 7.5x sales and 1.7x book value, with an EV/EBITDA of 17.5. Over the last twelve months it generated about $99M of revenue and $193M of net income. It runs a gross margin of 96.5%, an operating margin of 24.9% and a net margin of 172.1%. It shows return on equity of 136.6%, return on invested capital of 7.2% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 9.77. Over the past 52 weeks the share price ranged from $13.88 to $35.29, with a beta of 7.95.
Apnimed, Inc. does not currently pay a dividend.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Apnimed, Inc. (APMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.49% / 30% · (Cash+Inv) / Mkt Cap (36m) 39.8% / 30% · Interest income / Revenue 181400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.49% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 39.8% / 33% · Receivables / Mkt Cap (36m) 0.07% / 49% · Interest income / Revenue 181400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.49% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 39.8% / 33.33% · Receivables / Mkt Cap (24m) 0.07% / 33.33% · Interest income / Revenue 181400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 18.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.8% / 33.33% · Receivables / Avg Assets (4Q) 0.24% / 33.33% · Interest income / Revenue 181400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 10.7% / 33.33% · (Cash+ST Inv) / Total Assets 94.7% / 33.33% · (Cash+Recv) / Total Assets 94.9% / 33.33% · Interest income / Revenue 181400000.0% / 5% | Fail |
No. As of September 2026, Apnimed, Inc. (APMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Apnimed, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 181400000.0% of each dividend: Apnimed, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.